Cynthia Robinson
About
Cynthia Robinson is a scholar working on Infectious Diseases, Epidemiology and Health.
According to data from OpenAlex, Cynthia Robinson has authored 24 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 10 papers in Epidemiology and 5 papers in Health. Recurrent topics in Cynthia Robinson's work include Viral Infections and Outbreaks Research (16 papers), Hepatitis B Virus Studies (9 papers) and Viral Infections and Vectors (7 papers). Cynthia Robinson is often cited by papers focused on Viral Infections and Outbreaks Research (16 papers), Hepatitis B Virus Studies (9 papers) and Viral Infections and Vectors (7 papers). Cynthia Robinson collaborates with scholars based in Netherlands, Belgium and United States. Cynthia Robinson's co-authors include Macaya Douoguih, Kerstin Lühn, Viki Bockstal, Dickson Anumendem, Arnold E. Reif, Georgi Shukarev, Omu Anzala, Gaudensia Mutua, Deborah Watson‐Jones and Pontiano Kaleebu and has published in prestigious journals such as Nature Medicine, The Journal of Immunology and PLoS ONE.
In The Last Decade
Cynthia Robinson
22 papers receiving 323 citations
Peers
Cynthia Robinson
Srinivas Rao United States
Ana Maria Passos‐Castilho Brazil
Phu Dac Tran Vietnam
Roderick McPhee United States
Thomas Nørrelykke Nissen Denmark
Katrina M. Pollock United Kingdom
Momodou Cox Gambia
Ikbel Hadj Hassine Tunisia
Abishek Chandrashekar United States
Grieven P. Otieno Kenya
Citations per year, relative to Cynthia Robinson Cynthia Robinson (= 1×)
peers
Srinivas Rao
Countries citing papers authored by Cynthia Robinson
Since
Specialization
Citations
This map shows the geographic impact of Cynthia Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Robinson more than expected).
Fields of papers citing papers by Cynthia Robinson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Cynthia Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Robinson. The network helps show where Cynthia Robinson may publish in the future.
Co-authorship network of co-authors of Cynthia Robinson
This figure shows the co-authorship network connecting the top 25 collaborators of Cynthia Robinson. A scholar is included among the top collaborators of Cynthia Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cynthia Robinson. Cynthia Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Robinson, Cynthia, Benoît Baron, D. Lowson, et al.. (2025). Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy. Human Vaccines & Immunotherapeutics. 21(1). 2538340–2538340.
2.
Nyombayire, Julien, Susan Allen, Amanda Tichacek, et al.. (2025). Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial. Nature Medicine. 31(11). 3899–3906.
3.
Lacabaratz, Christine, Aurélie Wiedemann, Emile Foucat, et al.. (2024). Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial. The Journal of Infectious Diseases. 231(1). 230–240.
4.
Pollard, Andrew J., Catherine Schmidt‐Mutter, Fabrice Lainé, et al.. (2024). Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study. Vaccines. 12(2). 210–210.
5.
Robinson, Cynthia, Michael Katwere, Chelsea McLean, et al.. (2024). Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial. The Lancet Infectious Diseases. 24(7). 746–759.
6.
Surénaud, Mathieu, Cynthia Robinson, Viki Bockstal, et al.. (2024). Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. PLoS neglected tropical diseases. 18(4). e0011500–e0011500.
7.
Goldstein, Neil, Chelsea McLean, Auguste Gaddah, et al.. (2024). Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial. Human Vaccines & Immunotherapeutics. 20(1). 2327747–2327747.
8.
Robinson, Cynthia, Michael Katwere, Chelsea McLean, et al.. (2023). Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of Infectious Diseases. 229(4). 1068–1076.
9.
McLean, Chelsea, Karin Dijkman, Auguste Gaddah, et al.. (2023). Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans. Frontiers in Immunology. 14. 1215302–1215302.
10.
Bockstal, Viki, Georgi Shukarev, Chelsea McLean, et al.. (2022). First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. PLoS ONE. 17(10). e0274906–e0274906.
11.
Bockstal, Viki, Maarten Leyssen, Dirk Heerwegh, et al.. (2022). Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. npj Vaccines. 7(1). 156–156.
12.
Karita, Etienne, Julien Nyombayire, Susan Allen, et al.. (2022). Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial. Trials. 23(1). 513–513.
13.
Bockstal, Viki, Auguste Gaddah, Neil Goldstein, et al.. (2021). Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. npj Vaccines. 6(1). 157–157.
14.
Kitonsa, Jonathan, Zacchaeus Anywaine, Deborah Watson‐Jones, et al.. (2020). Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda. Global Health Action. 13(1). 1829829–1829829.
15.
Goldstein, Neil, Viki Bockstal, Stephan Bart, et al.. (2020). Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. The Journal of Infectious Diseases. 226(4). 595–607.
16.
Mutua, Gaudensia, Omu Anzala, Kerstin Lühn, et al.. (2019). Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. The Journal of Infectious Diseases. 220(1). 57–67.
17.
Nalamachu, Srinivas, et al.. (2014). A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain. Journal of Pain Research. 7. 669–669.
18.
Matas, Manuel & Cynthia Robinson. (1988). Diagnosis and Treatment of Monosymptomatic Hypochondriacal Psychosis in Chronic Renal Failure. The Canadian Journal of Psychiatry. 33(8). 748–750.
19.
Reif, Arnold E. & Cynthia Robinson. (1976). Enzymatic Degradation of Tumor Cells Damaged by Antibody Plus Complement. The Journal of Immunology. 117(2). 597–601.
20.
Reif, Arnold E., et al.. (1973). Acid phosphatase isozymes in cancer of the prostate. Cancer. 31(3). 689–699.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Srinivas Rao Breakdown of academic impact, for papers by Ana Maria Passos‐Castilho Breakdown of academic impact, for papers by Phu Dac Tran Breakdown of academic impact, for papers by Roderick McPhee Breakdown of academic impact, for papers by Thomas Nørrelykke Nissen Breakdown of academic impact, for papers by Katrina M. Pollock Breakdown of academic impact, for papers by Momodou Cox Breakdown of academic impact, for papers by Ikbel Hadj Hassine Breakdown of academic impact, for papers by Abishek Chandrashekar Breakdown of academic impact, for papers by Grieven P. Otieno